Drugs / SAR448501
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06647069 | Mar 2025 → Jun 2029 expected | rheumatoid arthritis, systemic lupus erythematosus | Sanofi | Recruiting | No outcome recorded |
| Phase 1 | NCT06392477 | Jul 2024 → Jan 2028 expected | B-cell non-Hodgkin lymphoma | Sanofi | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-05-27 | Sanofi | Press Release: Sanofi completes acquisition of DR-0201 sanofi.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAR448501 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06647069 ↗ |
| Known as | DR-0201 | “A Multicenter, Multiple Expansion Cohort Phase 1 Study Evaluating the Safety and Activity of SAR448501/DR-0201 as Multiple Ascending Doses in Patients With Relapsed/Refractory...” NCT06392477 ↗ |